581 related articles for article (PubMed ID: 27646734)
1. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
2. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
[TBL] [Abstract][Full Text] [Related]
3. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
[TBL] [Abstract][Full Text] [Related]
4. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
5. Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples.
van Nistelrooij AM; van Marion R; Koppert LB; Biermann K; Spaander MC; Tilanus HW; van Lanschot JJ; Wijnhoven BP; Dinjens WN
BMC Res Notes; 2017 Apr; 10(1):144. PubMed ID: 28376920
[TBL] [Abstract][Full Text] [Related]
6. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
7. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
9. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
10. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
[TBL] [Abstract][Full Text] [Related]
11. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
13. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.
Suzuki Y; Ng SB; Chua C; Leow WQ; Chng J; Liu SY; Ramnarayanan K; Gan A; Ho DL; Ten R; Su Y; Lezhava A; Lai JH; Koh D; Lim KH; Tan P; Rozen SG; Tan IB
Mol Oncol; 2017 Feb; 11(2):124-139. PubMed ID: 28145097
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
15. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
16. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
17. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
18. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
20. Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Chang YS; Tu SJ; Chen YC; Liu TY; Lee YT; Yen JC; Fang HY; Chang JG
Respir Res; 2021 Jan; 22(1):3. PubMed ID: 33407425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
